The FDA approved 13 new immunotherapies in 2025, down from 22 approvals in 2024, according to the Cancer Research Institute “Cancer Immunotherapy Insights & Impact” report published June 1.
The Cancer Research Institute tracks and analyzes FDA cancer immunotherapy approvals from 2011 through 2025 for the report.
Here are five things to know:
- Over the past 14 years, the FDA has approved 156 cancer immunotherapies.
- Eleven of the 13 immunotherapies approved by the FDA in 2025 were immune checkpoint inhibitors, which have also accounted for 77% of FDA immunotherapy approvals since 2011.
The remaining two immunotherapies approved in 2025 were a bispecific antibody and a cell and gene therapy. - The 13 immunotherapy approvals in 2025 were for:
- Bladder cancer: 2
- Colorectal and anal cancer: 2
- Esophageal cancer: 1
- Gastric cancer: 1
- Head and neck cancer: 2
- Hematological cancer: 2
- Lung cancer: 1
- Skin cancer: 1
- Multiple cancer types: 1
- Penpulimab — a PD-1 immune checkpoint inhibitor from Akeso Biopharma — became the first Chinese immunotherapy agent to receive FDA approval.
- The FDA approved the first immunotherapy for anal cancer in 2025, retifanlimab.
Read the full report here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
